Edition:
United Kingdom

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

6.60USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$6.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
117,835
52-wk High
$11.90
52-wk Low
$3.80

Select another date:

Wed, Nov 29 2017

BRIEF-Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data

* ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Aldeyra Therapeutics reports Q3 loss per share of $0.32

* Aldeyra Therapeutics announces third quarter 2017 financial results

BRIEF-Aldeyra ‍announcesd new data for ADX-102 from Phase 2 clinical trials

* Aldeyra - ‍announced new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis​

BRIEF-Perceptive Advisors buys 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19

* Perceptive Advisors Llc reports purchase of 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19 at $7.25 per share - SEC filing

BRIEF-Aldeyra Therapeutics posts pricing of public offering of common stock

* Aldeyra Therapeutics Inc announces pricing of public offering of common stock

BRIEF-Aldeyra Therapeutics announces proposed public offering of common stock

* Aldeyra Therapeutics Inc announces proposed public offering of common stock

BRIEF-Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial

* Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial Source text for Eikon: Further company coverage:

BRIEF-Aldeyra Therapeutics Q2 loss per share $0.35

* Aldeyra therapeutics announces second quarter 2017 financial results

BRIEF-Aldeyra Therapeutics expects to report results from phase 2A trial of topical ocular ADX-102 late in Q3

* Aldeyra Therapeutics-expects to report results from phase 2a trial of topical ocular ADX-102 late in Q3, 2017, not early in Q3 as stated in conf call Source text: (http://bit.ly/2rBbbkk) Further company coverage:

BRIEF-Aldeyra Therapeutics announces results from allergic conjunctivitis phase 2b clinical trial

* Aldeyra Therapeutics announces results from allergic conjunctivitis phase 2b clinical trial and plans for phase 3 clinical testing

Select another date: